• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Independence Blue Cross, TowerView Health Launches Medication Adherence Pilot Program

by HITC Staff 04/29/2015 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Towerview Health

The Independence Blue Cross (Independence) Center for Health Care Innovation announced this week that it will collaborate with TowerView Health and the Perelman School of Medicine at the University of Pennsylvania (Penn Medicine) on a pilot program to help chronically ill people who have multiple prescriptions make sure they take the right medication at the right time each day.

Pilot Details

People with health coverage from Independence Blue Cross who qualify for this study and choose to participate will be enrolled at no cost in a six month-long randomized pilot program directed by Penn Medicine researchers to evaluate if the program improves their medication adherence.

The participants will be divided into two groups:

– pilot group that receives help with medication adherence

– control group that receives no medication assistance.

TowerView will provide individuals in the study with five prefilled medication trays, each holding a week’s supply of medication. The tray fits inside an Internet-connected pillbox that can sense when members miss a dose of their medication and sends them reminders by phone, text, or email. For members without a cell phone, the pillbox is also equipped with lights and alarms to remind members to take their drugs. An integrated software platform notifies the Penn Medicine research coordinator when members haven’t been taking their medication over a period of time so that they can call to see if members need any additional assistance. TowerView’s services are sponsored by Independence and Penn Medicine.

TowerView Health Background

TowerView Health was founded in 2014 by four students after their college roommate and cofounder, Nick Valilis, was diagnosed with Acute Myeloid Leukemia during his first week of medical school. They created TowerView to help Valilis better manage his medications and hope the same approach can help others who take multiple medications. In 2014, TowerView participated in DreamIt Health to fine-tune its business model and meet potential customers.

TowerView is one of 11 startup companies that participated in the 2014 DreamIt Health Philadelphia class. Independence and Penn Medicine jointly sponsor the DreamIt Health new business accelerator and will sponsor the third annual DreamIt Health program, which began accepting applications for new participants this month. DreamIt Health will select up to 10 early-stage companies from applicants from around the world in the healthcare sector, based on the strength of their teams, their market potential, and their traction to date. In addition to a financial stipend, Dreamit Health provides these promising young companies with mentoring, business contacts, and other critical resources, including access to claims and clinical data and technology the companies need to shape and implement novel solutions.

In addition, TowerView won the 2015 HIMSS Venture+ Forum pitch competition held on April 12 in Chicago. HIMSS is the largest healthcare conference in the country that brings together over 38,000 health care IT professionals from around the world. Of the companies that applied for the competition, 15 startups were chosen to pitch live in front of a health care specific judging panel and audience of venture capitalists and strategic partners. 

One third to one half of all patients in the United States do not take their medication as directed, resulting in less than desirable outcomes and nearly $100 billion in avoidable hospital costs each year. Taking medication as directed is particularly difficult for people who are managing two or more chronic illnesses at the same time, like diabetes and high blood pressure.

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Paradigm Shift in Diabetes Care with Studio Clinics: Q&A with Reach7 Founder Chun Yong

Most-Read

Omada Health Launches "Nutritional Intelligence" with AI Agent OmadaSpark

Omada Health Soars in NASDAQ Debut, Signaling Digital Health IPO Rebound

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |